Skip to content

US · STVN · MEDICAL - INSTRUMENTS & SUPPLIES

Stevanato Group S.p.A. (STVN) intrinsic value and stock valuation

$15.65as of 2026-11-21 · Mkt cap 5.49B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Stevanato Group S.p.A. DCF and intrinsic value

InvestorsCraft values STVN with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from STVN’s statements →

Stevanato Group S.p.A. Graham Number

Graham Number: $7.76d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Piombino Dese, PD 35017 stevanatogroup.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$1.14B+11.5% 5y CAGRd
20192025
Net income
$134.3M+11.3% 5y CAGRd
20192025
Free cash flow
$21.4M-18.5% 5y CAGRd
20192025
Total equity
$1.49B+36.8% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$1.14B$1.1B$1.09B$983.7M$843.9M
Operating income$183.1M$161.1M$200.7M$192.4M$162.2M
Net income$134.3M$117.8M$145.6M$142.9M$134.3M
EPSd$491.9K$431.6K$549.6K$539.7K$507.4K
Operating cash flow$274.8M$155.8M$105.2M$103.3M$133.3M
Capital expenditure-$-253.35M-$-313.57M-$-441.93M-$-243.13M-$-113.18M
Free cash flow$21.4M-$-157.79M-$-336.72M-$-139.81M$20.2M
Total assets$2.54B$2.33B$2.07B$1.66B$1.42B
Total debt$470.7M$429M$396.6M$218.4M$244.3M
Net debt$340.2M$330.7M$327M-$-10.37M-$-166.75M
Total equity$1.49B$1.4B$1.13B$995.9M$841.7M
Cash and short-term investments$132.7M$98.3M$70.4M$256.7M$438.2M
Income statement
20252024202320222021
Revenue$1.14B$1.1B$1.09B$983.7M$843.9M
Cost of revenue$809.2M$801.7M$745.5M$663.9M$578.5M
Gross profit$330.3M$302.3M$339.9M$319.8M$265.4M
Research and development expenses$24.4M$31.7M$35.7M$34.4M$29.6M
Selling, general and administrative expenses$122.9M$118.6M$113.9M$111.8M$83M
Other expenses$0.00-$-9.09M-$-10.42M-$-18.85M-$-9.39M
Operating expenses$147.3M$141.2M$139.2M$127.4M$103.2M
Cost and expenses$956.4M$942.9M$884.6M$791.3M$681.7M
Interest income$12.5M$1.72M$790K$650K$550K
Interest expense$21.8M$6.86M$4.32M$3.94M$4.87M
Depreciation and amortization$85.1M$80.7M$78.5M$64.8M$56.4M
Ebitda$288.5M$247.8M$272.4M$256.4M$226.9M
Operating income$183.1M$161.1M$200.7M$192.4M$162.2M
Total other income/expenses, net-$-1.44M-$-850K-$-11.17M-$-4.79M$3.45M
Income before tax$181.6M$160.3M$189.6M$187.6M$165.7M
Income tax expense$47.4M$42.5M$43.9M$44.6M$31.4M
Net income$134.3M$117.8M$145.6M$142.9M$134.3M
Weighted average shares outstanding$273M$272.9M$265M$264.7M$264.7M
Weighted average diluted shares outstanding$273M$272.9M$265M$264.7M$264.7M
Balance sheet
20252024202320222021
Cash and short-term investments$132.7M$98.3M$70.4M$256.7M$438.2M
Net receivables$542.2M$529.9M$522.5M$369.5M$278.4M
Inventory$268.1M$245.2M$255.3M$213.3M$148.9M
Total current assets$934.4M$880.1M$861.9M$845.8M$866M
Property, plant and equipment, net$1.4B$1.26B$1.05B$660.7M$415.4M
Goodwill and intangible assets$86.8M$83.6M$81M$79.4M$79.2M
Long-term investments$6M$5.64M$5.15M$1.83M$1.97M
Total non-current assets$1.61B$1.45B$1.21B$813.9M$552.9M
Total assets$2.54B$2.33B$2.07B$1.66B$1.42B
Accounts payable$263.2M$231M$277.8M$239.2M$164.8M
Short-term debt$121.7M$111.9M$141.4M$70M$42.7M
Deferred revenue$43.8M$44.7M$58.8M$53.9M$50.6M
Total current liabilities$535.6M$477.5M$574.4M$462.5M$338.6M
Long-term debt$347M$317M$255.2M$148.4M$201.6M
Deferred revenue, non-current$98.8M$44.1M$39.4M$0.00$0.00
Total non-current liabilities$521.4M$447M$364.5M$201.3M$238.6M
Capital lease obligations$9.37M$16.9M$19M$20M$23.1M
Total liabilities$1.06B$924.4M$938.9M$663.8M$577.2M
Common stock$22.2M$22.2M$21.7M$21.7M$21.7M
Retained earnings$876.4M$863.4M$757.9M$623.4M$0.00
Accumulated other comprehensive income (loss)$55M-$-13.75M-$-9.11M-$-10.49M$686.1M
Total equity$1.49B$1.4B$1.13B$995.9M$841.7M
Total investments$8.2M$5.64M$5.9M$29.7M$29.1M
Total debt$470.7M$429M$396.6M$218.4M$244.3M
Net debt$340.2M$330.7M$327M-$-10.37M-$-166.75M
Cash flow statement
20252024202320222021
Net income$134.3M$160.3M$189.6M$187.6M$165.7M
Depreciation and amortization$83.9M$80.7M$78.5M$64.8M$56.4M
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital$48.6M-$-17.41M-$-102.48M-$-117.74M-$-41.63M
Accounts receivable$860K-$-3.83M-$-93.86M-$-46.42M-$-54.77M
Inventory-$-39.82M$12.3M-$-113.59M-$-107.37M-$-31.2M
Accounts payable$87.6M-$-25.89M$105M$36.1M$44.3M
Net cash provided by operating activities$274.8M$155.8M$105.2M$103.3M$133.3M
Investments in property, plant and equipment-$-264.18M-$-302.6M-$-433.23M-$-235.03M-$-107.69M
Acquisitions, net$1.79M-$-170K-$-3.59M$0.00$14.8M
Net cash used for investing activities-$-262.15M-$-310.21M-$-421.22M-$-242.95M-$-96.43M
Common stock issued$0.00$169.8M$0.00$0.00$380.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-14.16M-$-14.46M-$-14.29M-$-13.5M-$-11.2M
Net cash used for financing activities$21.2M$183.2M$158M-$-44.54M$254.9M
Net change in cash$43.9M$28.7M-$-159.14M-$-182.3M$295.4M
Cash at end of period$130.6M$98.3M$69.6M$228.7M$411M
Operating cash flow$274.8M$155.8M$105.2M$103.3M$133.3M
Capital expenditure-$-253.35M-$-313.57M-$-441.93M-$-243.13M-$-113.18M
Free cash flow$21.4M-$-157.79M-$-336.72M-$-139.81M$20.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Stevanato Group S.p.A.

        Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.

        CEO
        Franco Stevanato
        Employees
        6.01K
        Beta
        0.78

        Explore

        Frequently asked questions

        What is the intrinsic value of Stevanato Group S.p.A. (STVN)?

        Stevanato Group S.p.A. (STVN) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is STVN undervalued?

        STVN trades at a price of $15.65 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.